PURPOSE: TH-MYCN transgenic mice represent a valuable preclinical model of neuroblastoma. Current methods to study tumor progression in these mice are inaccurate or invasive, limiting the potential of this murine model. The aim of our study was to assess the potential of small animal positron emission tomography (SA-PET) to study neuroblastoma progression in TH-MYCN mice. PROCEDURE: Serial SA-PET scans using the tracer 2-deoxy-2-[(18)F]fluoro-D-glucose ((18)F-FDG) have been performed in TH-MYCN mice. Image analysis of tumor progression has been compared with ex vivo evaluation of tumor volumes and histological features. RESULTS: [(18)F]FDG-SA-PET allowed to detect early staged tumors in almost 100 % of TH-MYCN mice positive for disease. Image analysis of tumor evolution reflected the modifications of the tumor volume, histological features, and malignancy during disease progression. Image analysis of TH-MYCN mice undergoing chemotherapy treatment against neuroblastoma provided information on drug-induced alterations in tumor metabolic activity. CONCLUSIONS: These data show for the first time that [(18)F]FDG-SA-PET is a useful tool to study neuroblastoma presence and progression in TH-MYCN transgenic mice.
PURPOSE: TH-MYCNtransgenic mice represent a valuable preclinical model of neuroblastoma. Current methods to study tumor progression in these mice are inaccurate or invasive, limiting the potential of this murine model. The aim of our study was to assess the potential of small animal positron emission tomography (SA-PET) to study neuroblastoma progression in TH-MYCNmice. PROCEDURE: Serial SA-PET scans using the tracer 2-deoxy-2-[(18)F]fluoro-D-glucose ((18)F-FDG) have been performed in TH-MYCNmice. Image analysis of tumor progression has been compared with ex vivo evaluation of tumor volumes and histological features. RESULTS: [(18)F]FDG-SA-PET allowed to detect early staged tumors in almost 100 % of TH-MYCNmice positive for disease. Image analysis of tumor evolution reflected the modifications of the tumor volume, histological features, and malignancy during disease progression. Image analysis of TH-MYCNmice undergoing chemotherapy treatment against neuroblastoma provided information on drug-induced alterations in tumor metabolic activity. CONCLUSIONS: These data show for the first time that [(18)F]FDG-SA-PET is a useful tool to study neuroblastoma presence and progression in TH-MYCNtransgenic mice.
Authors: Loen M Hansford; Wayne D Thomas; Joanna M Keating; Catherine A Burkhart; Anne E Peaston; Murray D Norris; Michelle Haber; Patricia J Armati; William A Weiss; Glenn M Marshall Journal: Proc Natl Acad Sci U S A Date: 2004-08-16 Impact factor: 11.205
Authors: Christopher S Hackett; J Graeme Hodgson; Mark E Law; Jane Fridlyand; Kazutoyo Osoegawa; Pieter J de Jong; Norma J Nowak; Daniel Pinkel; Donna G Albertson; Ajay Jain; Robert Jenkins; Joe W Gray; William A Weiss Journal: Cancer Res Date: 2003-09-01 Impact factor: 12.701
Authors: Rosa F Hwang; Kenji Yokoi; Corazon D Bucana; Rachel Tsan; Jerald J Killion; Douglas B Evans; Isaiah J Fidler Journal: Clin Cancer Res Date: 2003-12-15 Impact factor: 12.531
Authors: Marta Terrile; Kenneth Bryan; Lynsey Vaughan; Albert Hallsworth; Hannah Webber; Louis Chesler; Raymond L Stallings Journal: PLoS One Date: 2011-12-02 Impact factor: 3.240
Authors: Jiaxiong Lu; Shan Guan; Yanling Zhao; Yang Yu; Sarah E Woodfield; Huiyuan Zhang; Kristine L Yang; Shayahati Bieerkehazhi; Lin Qi; Xiaonan Li; Jerry Gu; Xin Xu; Jingling Jin; Jodi A Muscal; Tianshu Yang; Guo-Tong Xu; Jianhua Yang Journal: Cancer Lett Date: 2017-04-26 Impact factor: 8.679
Authors: M Emmy M Dolman; Evon Poon; Marli E Ebus; Ilona J M den Hartog; Carel J M van Noesel; Yann Jamin; Albert Hallsworth; Simon P Robinson; Kevin Petrie; Rolf W Sparidans; Robbert J Kok; Rogier Versteeg; Huib N Caron; Louis Chesler; Jan J Molenaar Journal: Clin Cancer Res Date: 2015-07-22 Impact factor: 12.531